Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to evaluate the effect of 3M™ Clinpro™ Fluoride Aqueous Solution (experimental) on Dentin Hypersensitivity (DHS) in comparison to 3M™ Vanish™ (commercialized, control] in patients who have DHS.
Participants will be asked to complete the following activities:
Undergo a pre-treatment washout period for 3- to 6-weeks (± 4 days) post-enrollment. During this time, the Subject is to only use the provided oral hygiene products.
Hypersensitivity will be assessed prior to (baseline) and immediately after sample application.
Subject will be asked to come to the facility for hypersensitivity assessments at 24 hours, 7 days, and 30 days after the treatment visit.
Researchers will compare 3M™ Clinpro™ Fluoride Aqueous Solution to 3M™ Vanish™ to evaluate if the effect of Clinpro™ on DHS treatment is non-inferior to Vanish™.
After Informed Consent has been obtained, the subjects will be given study supplied oral hygiene products (e.g., toothbrush and toothpaste) to be used immediately after the consent visit and throughout the entire duration of the study.
Subjects will have a minimum wash-out period of 3 weeks followed by 1 treatment visit. At the treatment visit, a pain assessment will be performed (ie, a baseline pain score) in response to both an air-blast stimulus and tactile stimulus. After each stimulus, the Subject should score their pain using a Visual Analog Scale (VAS).
After recording baseline pain scores, Clinpro™ (Treatment arm) or Vanish™ (Control arm) will be applied according to the manufacturer's IFU. Pain in response to air blast and probe test will be assessed using VAS immediately after application of fluoride treatment (within 15 minutes). Pain response will be assessed again at 24 h, 7 d, 21 d and 30 d post-application of the treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 3M™ Clinpro™ Fluoride Aqueous Solution | Experimental | Investigational product. |
|
| 3M™ Vanish™ | Active Comparator | Commercialized product |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3M™ Clinpro™ Fluoride Aqueous Solution | Device | Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Pain From Baseline Immediately After Application of Test Product. | Change in sensitivity as assessed using a Visual Analog Scale (VAS, 0 - 100 mm) immediately after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Base line and immediately after application (within 15 minutes post-treatment). |
| Change in Pain From Baseline 24 Hours Post Application of Test Product. | This is a co-primary endpoint Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 24 hours after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Baseline and 24 hours post-treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Pain From Baseline 7 Days Post Application of Test Product. | Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 7 days after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Baseline and 7 days post-treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subject has medical (including psychiatric) and pharmacotherapeutic histories that may compromise the protocol - including the chronic use of anti-inflammatory, analgesic (pain), and mind-altering drugs; or analgesic (pain) medications within 48 hours prior to application of treatment.
Subject is pregnant (self-reported) or breast feeding.
Subject has allergies to product ingredients, eg, rosin, mint flavoring.
Subject has systemic conditions that are etiologic or predisposing to dentin hypersensitivity (eg, chronic acid regurgitation).
Subject has excessive dietary or environmental exposure to acids at time of screening.
Subject had periodontal treatment, bleaching treatments, or orthodontic treatments within previous 3 months or plans to have any other dental treatments during the study period.
Subject is enrolled in another clinical trial at the time of screening that would interfere with this study.
Subject is, in the opinion of the investigator, unsuitable for enrollment in the study for reasons other than those specified in the above exclusion criteria.
Individual teeth may not be included that meet any of the following criteria:
Study tooth has periodontal probing depth of ≥ 4 mm.
Study tooth or the surrounding supporting tissue has any other painful pathology or defects.
Study tooth has been restored in the preceding 3 months.
Study tooth is an abutment for fixed or removable prostheses or suffers traumatic malocclusion.
Study tooth is crowned or extensively restored and the restorations extending into the test area.
The tooth has dentin hypersensitivity due to cracked enamel.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yiming Li | Loma Linda University, School of Dentistry | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| LOMA LINDA UNIVERSITY, School of Dentistry | Loma Linda | California | 92350 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 3M™ Clinpro™ Fluoride Aqueous Solution | Investigational product. 3M™ Clinpro™ Fluoride Aqueous Solution: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. |
| FG001 | 3M™ Vanish™ | Commercialized product 3M™ Vanish™: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 3M™ Clinpro™ Fluoride Aqueous Solution | Investigational product. 3M™ Clinpro™ Fluoride Aqueous Solution: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. |
| BG001 | 3M™ Vanish™ |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Pain From Baseline Immediately After Application of Test Product. | Change in sensitivity as assessed using a Visual Analog Scale (VAS, 0 - 100 mm) immediately after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Posted | Mean | Standard Deviation | units on a scale | Base line and immediately after application (within 15 minutes post-treatment). |
|
AEs will be collected from the time of initial application of control or investigational treatment until end of study visit (30 days post-application).
No adverse event was reported in this study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 3M™ Clinpro™ Fluoride Aqueous Solution | Investigational product. 3M™ Clinpro™ Fluoride Aqueous Solution: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Helen Han | Solventum | 6517856568 | mhan3@solventum.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 27, 2023 | Nov 6, 2024 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003807 | Dentin Sensitivity |
| ID | Term |
|---|---|
| D014076 | Tooth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Only subject will be blinded.
| 3M™ Vanish™ | Device | Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. |
|
| Change in Pain From Baseline 21 Days Post Application of Test Product. | Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 21 days after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Baseline and 21 days post-treatment |
| Change in Pain From Baseline 30 Days Post Application of Test Product. | Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 30 days after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Baseline and 30 days post-treatment |
Commercialized product
3M™ Vanish™: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Air Blast VAS (Visual Analog Scale) baseline | The baseline pain score upon air blast stimulus was measured using Visual Analog scale (VAS) prior to the sample application. The VAS ranges from 0 mm to 100 mm. 0 mm is no pain, and 100 mm is worst pain. Higher scores mean a worse outcome. | Mean | Standard Deviation | units on a scale |
|
Commercialized product
3M™ Vanish™: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
|
|
|
| Primary | Change in Pain From Baseline 24 Hours Post Application of Test Product. | This is a co-primary endpoint Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 24 hours after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Posted | Mean | Standard Deviation | units on a scale | Baseline and 24 hours post-treatment |
|
|
|
|
| Secondary | Change in Pain From Baseline 7 Days Post Application of Test Product. | Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 7 days after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Posted | Mean | Standard Deviation | units on a scale | Baseline and 7 days post-treatment |
|
|
|
|
| Secondary | Change in Pain From Baseline 21 Days Post Application of Test Product. | Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 21 days after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Posted | Mean | Standard Error | units on a scale | Baseline and 21 days post-treatment |
|
|
|
|
| Secondary | Change in Pain From Baseline 30 Days Post Application of Test Product. | Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 30 days after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome. | Posted | Mean | Standard Deviation | units on a scale | Baseline and 30 days post-treatment |
|
|
|
|
| 0 |
| 51 |
| 0 |
| 51 |
| 0 |
| 51 |
| EG001 | 3M™ Vanish™ | Commercialized product 3M™ Vanish™: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity. | 0 | 50 | 0 | 50 | 0 | 50 |
Not provided
Not provided